| Factor Information | |
|---|---|
| Data ID | 4001 |
| Factor | Kidney Injury Molecule(KIM 1)(pg/mg) |
| Description | Urinary levels of kidney in- jury molecule-1/creatinine were significantly higher in subjects with congenital heart disease when compared to those without congeni- tal heart disease. |
| Biomarker | YES |
| Classification | A6 (clinical factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To determine if young adults with congenital heart disease have differences in the baseline concentration of urinary tubular biomarkers when compared to healthy young adults. |
| p Value | 0.01 |
| Conclusion | Our study suggest young adults with congenital heart disease may have subclinical kidney dysfunction. Lower levels of IGFBP7 and TIMP2 may indicate an impaired ability to respond to injury, while higher levels of kidney injury molecule-1 may reflect early tubular injury. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 744 |
| CHD Type | isolated CHD |
| CHD Subtype | D-TGA/BAV/TOF/CoA/NA/AVSD/AS/VSD |
| Reference | |
|---|---|
| PMID | 31793232 |
| Year | 2019 |
| Title | Baseline tubular biomarkers in young adults with congenital heart disease as compared to healthy young adults: Detecting subclinical kidney injury |
| Sample | ||
|---|---|---|
| Population | young adults | |
| Source | patients' blood | |
| Region | Pittsburgh, USA | |
| Method | Urinary tissue inhibitor of metalloproteinases-2, insulin-like growth factor binding protein 7 and the product of tissue inhibitor of metalloproteinases-2 and in- sulin-like growth factor binding protein 7 ([tissue inhibitor of metal- loproteinases-2]•[insulin-like growth factor binding protein 7]) was measured with the NephroCheckTM Test (Astute Medical, San Diego, CA, USA) | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | medication with Metoprolol/Aspirin/Warfarin/Furosemide, etc | |
| Group | young adults with CHD(Treatment) | health young adults(Control) |
| Number | 30 | 30(healthy young adults) |
| Age | 28 (26-31) years | 27 (22-30) years |
| Gender (Male: Female) | male:66.7% | male:56.7% |
| Marker Level | 576.50 (351.71-996.52)(pg/mg) | 332.77 (206.85-608.00)(pg/mg) |
